Press communication
Lund, Sweden, May 31, 2024
This is a translation of the Swedish press release published 2024-05-31

Neola Medical AB (publ) is pleased to announce the appointment of David Folkesson as Chief Financial Officer, effective August 26, 2024.

David Folkesson brings extensive experience as a CFO in both public and private companies. He has previously worked as an auditor at Deloitte and as a financial advisor at Pragati. With his expertise in financial reporting, accounting, financial management, and business development, David will enhance Neola Medical’s financial operations and contribute to building a profitable business.

“We are delighted to welcome David Folkesson to Neola Medical. He brings valuable insights from various companies, and with his business- and results-oriented experience, he will be a key player in our growth journey and commercialization phase, particularly as we approach market launch in the USA,” says CEO Hanna Sjöström.

“I look forward to joining Neola Medical’s exciting growth journey and contributing to bringing Neola® to clinics to improve the care of preterm born infants,” says David Folkesson, incoming CFO at Neola Medical.

David Folkesson will assume his role as CFO at Neola Medical on August 26, 2024.

Read the Swedish press release here: Ny CFO på Neola Medical inför marknadslansering i USA

For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 (0)760-10 71 16, e-mail:

Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at The company’s Certified Adviser is FNCA Sweden AB.